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Abstract 
Size and shape have progressively appeared as some of the key factors influencing the 
properties of nanosized drug delivery systems. In particular, elongated materials are thought to 
interact differently with cells and therefore may allow alterations of in vivo fate without 
changes in chemical composition. A challenge, however, remains the creation of stable self-
assembled materials with anisotropic shape for delivery applications that still feature the ability 
to disassemble, avoiding organ accumulation and facilitating clearance from the system. In this 
context, we report on self-assembled cyclic peptide-polymer conjugates that self-assemble into 
supramolecular nanotubes, as confirmed by SANS and SLS. Their behaviour ex and in vivo 
was studied: the nanostructures are non-toxic up to a concentration of 0.5 g.L-1 and cell uptake 
studies revealed that the pathway of entry was energy-dependent. Pharmacokinetic studies 
following intravenous injection of the peptide-polymer conjugate and the control polymer to 
rats showed that the larger size of the nanotubes formed by the conjugate reduced renal 
clearance and elongated systemic circulation. Importantly, the ability to slowly disassemble 
into small units allowed effective clearance of the conjugates and reduced organ accumulation, 
making these materials interesting candidates in the search for effective drug carriers.  
Keywords 
Peptide-polymer conjugates, supramolecular nanotubes, radiolabelling, pharmacokinetics, 
biodistribution. 
Introduction 
Nanomedicine, and the use of drug delivery systems in particular, has been shown to reduce 
drug related side effects and thus to allow for higher drug dosing.1-2 Nanosized carriers with 
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stealth like surface permits enhanced circulation times by avoiding immediate renal filtration 
and unspecific organ accumulation, which can enable passive targeting to tumors by the 
enhanced permeability and retention (EPR) effect.3-4 Delivery vectors also provide shielding 
of the drug,5 and allow for the introduction of targeting moieties,6-8 thus reducing side effects 
and enhancing drug delivery efficiency. Amultitude of drug delivery vectors have been 
explored in the past decades with variable degree of success, including inorganic (gold 
nanoparticles,9 quantum dots,10 silica nanoparticles11) and organic (lipid formulations,12-13 viral 
nanoparticles,14 carbon nanotubes15 or polymer-based structures16) carriers.  
Shape has progressively appeared as one of the features that may influence the in vivo 
behaviour of carriers, with elongated structures attracting increasing attention.17 Some studies 
have shown that because of their increased aspect ratio, elongated nanoparticles exhibit longer 
circulation times and can enhance tumour accumulation in vivo.18 Filomicelles,19 polymer 
brushes20 and PEGylated tobacco mosaic viruses21-22 are among organic tubular structures that 
have shown promising results in vivo. Discher et al. have, for example, studied filomicelles 
and compared their behaviour to that of their spherical counterparts in mice models.23 They 
showed that large cylindrical structures of 2-18 µm in length enable much longer circulation 
times and higher loading of the anticancer agent Paclitaxel in comparison to spherical particles 
while maintaining similar tumour accumulation and survival rates. Müllner et al. have studied 
the pharmacokinetics of unimolecular cylindrical polymer brushes (with lengths ranking from 
35 nm to 1200 nm) in rats, showing that they exhibit long term blood circulation, and that the 
aspect ratio of the brushes has a considerable impact on their pharmacokinetic parameters.24 
They further studied this system in mouse xenografts, demonstrating that the brushes undergo 
EPR and passively target tumour tissues.25 The main limitation of such large stable objects is 
their high stability in vivo leading to relatively poor clearance, which may lead to recognition 
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by the mononuclear phagocytic system (MPS) translating to high accumulation in organs such 
as the spleen and the liver.26  
One way to circumvent this issue is to explore the use of materials which undergo 
supramolecular self-assembly, for example by directed hydrogen bonds formation.27-29 
Supramolecular polymers,30 especially those that self-assemble in aqueous media,31 have 
started to gain considerable attention in the field of nanomedicine.27 They allow for a bottom-
up design strategy that enables extensive functionalization of the building blocks, resulting in 
broad libraries of assembled materials. Examples include systems based on host-guest 
interactions,32 or on the stacking of peptide amphiphiles into fibres.33-35 One possible major 
advantage of self-assembling structures over other nanoparticles is their supramolecular nature 
which provides initial stability, but eventually allows the structures to break up into unimeric 
entities small enough to be cleared out of the system, hence avoiding undesired organ 
accumulation.  
An emerging class of elongated drug carriers that feature such a supramolecular structure are 
nanotubes comprising cyclic peptide-polymer conjugates.36 Cyclic peptides formed of an even 
number of alternating D- and L- amino acids have been shown to adopt a flat conformation 
leading to stacking into nanotubes through antiparallel β-sheet formation.37 Conjugation of 
water-soluble polymers to these peptides enables control over the size and the functionality of 
the nanotubes. Although first cell studies indicated that nanotubes possess great potential as 
nanosized drug delivery systems,38-40 their in vivo behaviour has yet to be explored.  
Here, we synthesized poly(hydroxypropyl methacrylamide) (pHPMA)-based cyclic-peptide 
polymer conjugates and examined their ability to self-assemble into nanotubes. A non-
assembling polymer which does not contain the peptide core was also synthesised as a control. 
After selection of the most promising candidate, the in vitro behaviour of both conjugate and 
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control polymer, as well as their pharmacokinetics and biodistribution in rats were studied and 
compared.  
 
Results and discussion 
Design and synthesis 
The choice of a polymer that is pharmaceutically relevant is critical when designing a drug 
delivery vector, which is why pHPMA was chosen. During the past decades, pHPMA has been 
extensively studied in the context of cancer therapy41 and several polymer-drug conjugates 
based on this polymer are in different stages of clinical trials.42-43 In addition to its high 
biocompatibility, pHPMA can be accessed by radical polymerization methods, which 
facilitates the introduction of comonomers and the formation of defined end-groups. Three 
pHPMA-cyclic peptide conjugates were synthesized, using Reversible Addition Fragmentation 
Chain Transfer (RAFT) polymerization (see details in materials and methods section and 
supporting information) followed by coupling of the polymer to the chosen cyclic peptide, 
cyclo(D-Leu-Lys-D-Leu-Trp)2 (Scheme 1 and  
Table 1). Two different degrees of polymerization (DP) were targeted for HPMA 
homopolymers (P1, DP = 25 and P2, DP = 50). A third polymer (P3, DP = 50) incorporating 
a small percentage of a pyridine-containing comonomer (PUEMA), which provides a handle 
for attachment of organometallic drugs, was also prepared to test the influence of functional 
handles introduction in the system.  
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Scheme 1. Synthesis of polymers P1-4 and conjugates C1-3. (i) HPMA, VA 044, DMSO/H2O 
(opt: 5% PUEMA). (ii) cyclo(D-Leu-Lys-D-Leu-Trp)2, HBTU, NMM, DMSO. 
 
As expected from RAFT polymerization, all obtained polymers P1-3 displayed low dispersities 
≤ 1.15. The polymers were subsequently attached to cyclo(D-Leu-Lys-D-Leu-Trp)2, via amide 
bond formation between the carboxylic acid chain end of the polymers and the two lysine 
residues present on the cyclic peptide, using O-(benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HBTU) as a coupling reagent in the presence of an 
organic base, to form a stable amide bond.44-46 The obtained peptide-polymer conjugates C1-3 
were purified by dialysis and isolated. Size exclusion chromatography (SEC) analysis revealed 
that low dispersities (≤ 1.20) were maintained (see Figure S1 for SEC chromatograms). 
Table 1. Summary of polymers and conjugates used in this work. 
Entry Material 
Mn, tha 
(g.mol-1) 
Mn, GPCb 
(g.mol-1) 
Ðb 
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P1 pHPMA25 3900 7000 1.10 
C1 CP-(pHPMA25)2 8800 14200 1.13 
P2 pHPMA53 7800 11700 1.10 
C2 CP-(pHPMA53)2 16600 27900 1.12 
P3 p(HPMA55-co-PUEMA3.5) 9100 11900 1.10 
C3 CP-(p(HPMA55-co-PUEMA3.5))2 19200 24600 1.18 
P4 pHPMA93-co-PUEMA7 15700 21400 1.12 
P5 RhB-pHPMA58-co-PUEMA4 9700 14900 1.10 
C5 CP-(RhB-pHPMA58-co-PUEMA4)2 20400 28300 1.13 
P6 RhB-pHPMA98-co-PUEMA8 15700 20500 1.20 
 
a Determined by 1H NMR. b Determined by SEC using DMF (0.1% LiBr) as eluent, calibrated with pMMA standards.  
Characterization of supramolecular nanotubes 
Small angle neutron scattering (SANS) measurements were conducted on conjugates C1-3 in 
aqueous solution (deuterated PBS) in order to assess their self-assembly and elucidate key 
structural parameters, such as shape (using the q-dependency of the scattered intensity) and 
dimensions (using the intensity at low q values).47 
 
Figure 1. A) Small angle neutron scattering profiles of C1 at 10 mg.mL-1 (orange squares), C2 
at 5 mg.mL-1 (green diamonds), C3 at 5 mg.mL-1 (purple circles) in PBS and their fits using 
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cylindrical micelle (orange line), Gaussian chain (green line) and flexible cylindrical micelle 
(purple line) models, respectively. B) Schematic representation of the three conjugates in 
solution.  
 
Interestingly, all three conjugates exhibit very different scattering profiles (Figure 1A). Data 
for both homopolymer-based conjugates C1 and C2 show a plateau at low q values, indicative 
of a finite length, while a q-1 dependency is observed for C3 in that q range, characteristic of a 
longer cylindrical structure. In the case of C2, the data is best fitted with a Gaussian chain 
model, which represents non-assembled polymer chains in solution (see supporting 
information, Table S2 and Figure S2). In contrast, models corresponding to assembled 
structures were necessary to fit the data corresponding to the other two conjugates. More 
precisely, cylindrical micelle models (worm-like) were used to fit the data for C1 and C3, as 
they take into account both the cylindrical shape provided by the cyclic peptide core self-
assembled into nanotubes (characteristic q-1 dependency at low q values: cylinder form factor) 
and the polymer arms (Gaussian chain form factor at high q values).48 For these models, a 
radius of 5 Å was used for the peptide core, in accordance with previously reported results.36 
Using these parameters, reasonable values confirming the elongated shape of the structures 
were obtained (see supporting information, Tables S3 and S4, Figures S3 and S4). In the case 
of C1 a nanotube length of about 5.2 nm was obtained, which corresponds to a aggregation 
number of 11, calculated using the previously reported distance between adjacent peptides33,40 
(4.7 Å).   
In the case of C3, precise information on length could not be obtained solely using SANS, 
therefore static light scattering (SLS) measurements were carried out in parallel to SANS in 
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order to widen the window of observation and obtain scattering intensity values for lower q 
values (Figure 2). 
 
Figure 2. Static light scattering profile of C3 (CP-(p(HPMA-co-PUEMA))2) in solution in PBS 
at different concentrations. 
Results show that the molecular weight of the assemblies was within the tested range 
independent of conjugate concentration and was found to be 6.15.105 ± 0.86.105 g.mol-1 (see 
Figure S5 and Table S5). These observations are in agreement with the results of Catrouillet et 
al. on self-assembling bis- and tris(urea)s decorated by polymer arms, in which the length of 
the obtained assemblies did not show concentration dependence, contrary to what could be 
expected of other supramolecular systems.49 Using this result together with the molecular 
weight of the unimer and the distance between adjacent peptides, an aggregation number of 34 
± 5, and an average length of 16.0 ± 2.3 nm, were determined. The aspect ratio of these 
nanotubes was estimated to be around 2.9 (see supporting information). It is important to note 
that this value is an estimate, as it is difficult to determine the dimensions of the polymeric 
shell in solution with accuracy.  
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The noticeable difference in assembly patterns for the three conjugates (see Figure 1B for a 
schematic representation) is likely due to the nature of the polymers attached to the cyclic 
peptide, with a combination of steric hindrance and hydrogen bonding capacity influencing the 
stacking of the conjugates. Comparing C1 and C2, which are based on different length 
homopolymers of HPMA (DP 25 and 53, respectively), it seems reasonable to conclude that 
the longer polymer chains in C2 hindered the self-assembly process, such that the conjugate 
C1 formed short cylinders (Nagg = 11) whereas C2 remained as unimers in solution. This result 
is in line with previously reported work, which showed a decrease in tube length with 
increasing polymer molecular weight,50-51 and with the general concept of frustrated growth of 
supramolecular systems induced by steric hindrance.52 The differences in self-assembly 
between C2 and C3 are the most striking, since they have comparable molecular weights but 
contrasting morphologies in solution. The homopolymer-based C2 did not assemble while C3, 
which contains 5% of the comonomer PUEMA, stacked into elongated tubes (Nagg = 34 ± 5). 
We attribute the differences in morphology to the presence of urea bonds and pyridine motifs 
in PUEMA, which provide additional hydrogen bonding and π-π stacking sites, respectively, 
thereby counterbalancing the steric hindrance caused by the long polymer chains, and 
strengthening the overall assembly. 
 
In vitro studies 
The interactions with cells of the nanotubes obtained from the self-assembly of C3 were 
investigated next.. A non-self-assembling polymeric equivalent (P4) was synthesized in a 
similar manner to P1-3 using a bifunctional CTA (see Scheme 1, Table S1 and materials and 
methods section for details on the synthesis,  
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Table 1 and Figure S1 for for SEC results). 
The biocompatibility of the conjugate C3 and the corresponding polymer control P4 was tested 
in vitro on three cell lines (A2780 human ovarian carcinoma, PC3 human prostate carcinoma 
and MDA-MB-231 breast cancer) by performing cell growth inhibition assays for 72h. In all 
three cell lines, incubation with up to 0.5 g L-1 of the compounds did not result in any noticeable 
reduction in cell viability (Figure 3A-C). 
 
Figure 3. Toxicity profile of the compounds (continuous: conjugate, dashed: polymer) in A) 
A2780 B) PC3 and C) MDA cells, and cellular fluorescence intensity associated with 
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rhodamine as determined by flow cytometry after incubation of the compounds for 3h at 4 °C, 
3h at 37 °C and 24h at 37 °C in D) A2780 E) PC3 and F) MDA cells. Data represents geometric 
mean of fluorescence ± SD for two independent experiments done in triplicates: *p < 0.05, 
***p < 0.001, ****p < 0.0001. 
Cellular association of the nanotubes and of the non-assembling control was subsequently 
quantified using flow cytometry (Figure 3D-F). To facilitate detection, a rhodamine monomer 
was copolymerized with HPMA and PUEMA following similar procedures to those used for 
the materials described above, to afford rhodamine-labelled conjugate C5 and polymer P6  with 
concentrations in rhodamine kept below 0.1 % of total monomer content (Scheme 2, see 
Scheme S1, Table S1 and materials and methods section for details on the synthesis, Table 1 
and Figure S1 for SEC results.). 
 
Scheme 2. Synthesis of polymer P5, conjugate C5 and polymer P6. (i) HPMA, 5% PUEMA, 
0.1% RhMA, VA 044, DMSO/H2O. (ii) cyclo(D-Leu-Lys-D-Leu-Trp)2, HBTU, NMM, DMSO. 
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The amount of rhodamine monomer was kept below 0.1 % of total monomer content to avoid 
disruption of the self-assembly process and interference with biological behaviour. Corrections 
factors were used to enable comparison between the two compounds, similar amounts of 
polymer were used in all cases and data was corrected according to fluorescence intensity (see 
supporting information, Figure S6 and Table S6). Cells were incubated in presence of the 
compounds for 3h and 24h at 37 °C. In both cases and in all three cell lines, the polymer control 
associated significantly less than the conjugate (p < 0.0001). For example in A2780, the amount 
of conjugate C5 measured in the cells was nearly double that of polymer P6 after 3h; the 
discrepancy increased to 3.5 times more conjugate after 24h incubation. We attribute this result 
to the difference in size and aspect ratio between the two systems, given the fact that the 
conjugates self-assemble in these conditions to form a cylindrical assembly with an average 
aggregation number of 34, whereas the polymer P6 remains as a single unit. Particle shape53 
and size54-56 are thought to play a non-negligible role in cellular uptake, with larger particles 
exhibiting increased uptake, up to a certain size, above which the uptake generally decreases. 
Although results vary across studies, uptake appears to be most efficient between 20 and 100 
nm, with particles with a diameter of either less than 10 nm or more than 100 nm entering the 
cells less than those of intermediate size. This effect is found across particles of differing 
nature, including coated iron oxide,54 silica55 and polymeric56 nanoparticles. The present results 
are in line with these findings, with 16 nm-long nanotubes entering the cells to a higher extent 
than single polymer chains.  
Cellular association increases over time, indicating that uptake occurs to a greater extent than 
excretion. In the case of peptide-polymer conjugate C5, a 3-fold increase in fluorescence in 
MDA cells was observed when varying the incubation time from 3h to 24h. Similar increases 
were found in other cell lines, with 3.8x in PC3 and 3.9x in A2780. This effect was also 
observed for the polymer, although to a lesser extent, and increases in fluorescence of 2.4x 
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between 3h and 24h incubation with A2780 cells, 1.6x with PC3 and 2.0x with MDA were 
recorded. In summary, these results indicate that the compounds accumulate in the cells over 
time (uptake > exocytosis), a phenomenon which is commonly observed for nanosized 
objects.57-58 
In order to probe whether the mechanism of internalization was energy-dependent, the 
experiment was also performed at 4 °C, a temperature at which energy dependent uptake 
pathways are blocked. In all three cell lines, both compounds showed no accumulation after 3h 
under these conditions, suggesting that the mechanism of cellular entry relies on endocytosis 
or other energy-dependent pathways. 
Intracellular localization of the conjugate was confirmed by confocal microscopy, using the 
rhodamine-labelled compound C5 (Figure 4). Following incubation of PC3 cells with the 
conjugate at 20 μM for 24h, rhodamine staining inside the cells confirmed that the compound 
was readily taken up by the cells and not simply associated with the membrane. Control 
experiments are shown in supporting information (Figure S7). Lysotracker ® green was added 
together with the conjugate to assess organelle localization. The merged images of the red and 
green channels clearly demonstrate colour coincidence of the conjugate with the lysosomal 
compartments, which is in agreement with the flow cytometry data, suggesting uptake of the 
compound occurs via endocytosis.  
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Figure 4. Confocal images of PC3 human prostate carcinoma cells treated with rhodamine-
labelled conjugate C5 for 24 h at 37 °C at a concentration of 20 μM. Lysosomes were stained 
using Lysotracker ® Green DND-26. Scale bar 20 μm. 
 
Plasma pharmacokinetics and organ biodistribution 
In order to quantitatively monitor the characterize the in vivo behaviour of the self-assembling 
peptide-polymer conjugates, both the conjugate C3 and corresponding control polymer P4 
were radiolabelled, taking advantage of the hydroxyl groups present on pHPMA to attach 
[14C]-ethanolamine (Scheme 3). Although the extent of labelling was kept below 1% of 
HPMA units to avoid any potential influence of the chemical modification, we cannot 
completely exclude an influence of the label on self-assembly or in vivo behaviour of the 
polymers or nanotubes Nevertheless, the chemical alteration induced by the radioactive 
labelling is minor and is not expected to alter the physical and bio-properties of the 
conjugates.59-61  
 
Scheme 3. Radiolabelling of compounds C3 and P4. 
The obtained compounds C3* and P4* were purified by size exclusion chromatography (SEC) 
and extensively dialysed to remove any excess radiolabel. Effective labelling was confirmed 
by HPLC analysis and scintillation counting of SEC fractions (Figures S8 and S9);  polymer 
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P4* and conjugate C3* were found to have specific activities of 0.28 µCi/mg and 0.33 µCi/mg, 
respectively. The radiolabelled polymer P4* and conjugate C3* were subsequently injected 
intravenously to male Sprague Dawley rats at a dose of 12 mg.kg-1 and blood samples taken at 
regular intervals for 24h to determine the plasma concentration versus time profiles (Figure 5). 
Taking into account the weight (~ 300 g) and blood volume (~ 20 mL) of the Sprague Dawley 
rats, the 12 mg.kg-1 dose corresponds to 0.5 mg.mL-1 at the injection time, concentration at 
which the conjugates are assembled into 16-nm long tubes as determined by SLS (see above).  
 
Figure 5. Plasma concentration versus time profiles of [14C]-labelled polymer P4* (orange 
squares) and conjugate C3* (purple circles) following intravenous administration to rats at 12 
mg.kg-1 (mean ± SD, n = 4-5 rats). 
 
The non-compartmental (NC) pharmacokinetic parameters taken from the plasma profiles are 
summarized in  
Table 2.  
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The initial volume of the central compartment (Vc) was close to blood volume, which is typical 
for high molecular weight materials that do not rapidly distribute out of the vasculature. The 
non-assembling polymer P4* showed relatively rapid clearance from the systemic circulation, 
in accordance with previously reported data for HPMA copolymers.61-64  
In contrast, plasma exposure (AUC) of the nanotubes was significantly higher (>3 fold) than 
that of the polymer (p < 0.0001) and the increased exposure was reflected in reduced clearance 
(3 ± 0.2 mL.h-1 for the nanotubes vs 12 ± 0.4 mL.h-1 for the polymer). The terminal volume of 
distribution (Vd,β) was also significantly lower for the nanotubes (70 ± 2 mL for the nanotubes 
vs 225 ± 35 mL for the polymer chains). The combination of reductions in clearance and 
volume of distribution dictated that the elimination half-life of the nanotubes was relatively 
unchanged and only slightly longer than that of the polymer control. This parameter is 
calculated from the slope of the elimination phase that occurs after the rapid decrease of 
compound concentration during the distribution phase. In contrast to the distribution half-life, 
which corresponds to the distribution of compound from the blood circulation to the body 
tissues – it relates to drug metabolism and excretion, and is typically used to compare 
pharmacokinetic parameters.65-66 We attribute the differences in systemic pharmacokinetics 
between polymer P4* and conjugate C3* to the larger size of the nanotubes formed by C3*, 
which reduces distribution and allows them to partially avoid immediate renal clearance. The 
observed volume of distribution of the nanotubes is lower than for small molecular weight 
linear polymers, but higher than the reported values for PEGylated dendrimers (as low as 25 
mL after 30h),67 stars (approximately 60 mL after 7 days)65 or small brushes (60 mL after 
24h).24 
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Table 2. Calculated pharmacokinetic parameters and urine recovery after intravenous 
administration of conjugate C3* and polymer P4* to rats at 12 mg.kg-1 (mean ± SD, n = 4-5 
rats). **p < 0.01, ****p < 0.0001. 
 Conjugate (C3*) Polymer (P4*) 
t1/2 (h) 16.1 ± 1.3 13.4 ± 2.0 
AUC (μg.mL-1.h) 1120 ± 62 331 ± 10**** 
Vc (mL) 15.0 ± 1.0 16.6 ± 1.0 
Vd,β (mL) 70 ± 2 225 ± 35** 
Cl (mL.h-1) 3 ± 0.2 12 ± 0.4**** 
Urine (% dose) 62 ± 7 72 ± 8 
 
The percentage of dose recovery in urine after 24h was high for both the polymer chains (72 ± 
8 %) and the conjugates (62 ± 7 %), indicating that the majority of both compounds is 
ultimately excreted from the body. The molecular weight cut-off for renal filtration is generally 
estimated to be around 50 kDa for hydrophilic polymers such as PEG or dextran26 which is 
well below the molecular weight of the nanotubes (615 kDa, as determined by SLS) but above 
the mass of the polymer and the conjugate. Hence, this result suggests that the labelled 
compounds found in urine are fragments of the initial nanotubes, either degraded chemically 
(free radiolabel), or physically (unimeric conjugates or very short tubes).  
In addition to the NC analysis the data was also fitted to a two-compartmental model (see 
materials and methods section and supporting information, Table S7 and Figure S10). Relevant 
pharmacokinetic parameters including t1/2, AUC, Vd and Cl calculated from the compartmental 
model correlated well with those derived from the NC analysis (Table S8). In particular, the 
higher AUC observed for the nanotubes is maintained, with 1007 ± 153 µg.mL-1.h obtained 
using the two-compartmental model (vs 1120 ± 62 µg.mL-1.h using the NC model), compared 
to the values obtained for the polymer control (272 ± 68 µg.mL-1.h and 331 ± 10 µg.mL-1.h for 
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the two-compartmental and NC models, respectively). These results indicate confidence in the 
comparisons between the polymer and conjugate using either approach. 
To clarify the fate of both compounds after administration, and to verify that they were both 
largely excreted from the body within 24h, accumulation in major organs (liver, spleen, 
pancreas, kidneys, heart, lungs, brain) was quantified by measuring the residual [14C] content 
present in the ex vivo tissues harvested 24h after IV injection. Figure 6 shows the percentage 
of injected [14C] recovered in each organ. Levels of accumulation were very low across all 
examined organs (cumulative % dose recovered < 5%), with the highest amount found in the 
liver (3.1 ± 0.4 % for the conjugate, 1.3 ± 0.3 % for the polymer). Note that organs were not 
perfused, so residual [14C] content could be due to blood, suggesting an even lower level of 
accumulation. Such low levels of organ accumulation are typical of small molecular weight 
HPMA copolymers,64 and indicate that the compounds are either eliminated or still circulating 
systemically.  
 
Figure 6. Distribution of [14C] in organs, 24h after intravenous administration of conjugate 
(purple) and polymer (orange) at 12 mg.kg-1 (mean ± SD, n = 4-5 rats). 
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The very low levels of organ uptake, together with the high urine excretion, and the 
intermediate value of Vd (lower than for a small molecular weight polymer but higher than for 
dendrimers, stars or small brushes) are consistent with the dynamic nature of the nanotubular 
structures. The results suggest that the peptide-polymer conjugates are initially present in 
plasma predominantly as the assembled nanotubes, the size of which precluded renal clearance 
and extravasation, but that over time disassembly results in the generation of unimeric 
conjugates that are more readily distributed and renally cleared, thereby avoiding organ 
accumulation. Nevertheless, further studies are required to more fully elucidate the 
mechanisms of distribution, metabolism and clearance.  
 
Conclusions 
Peptide-polymer conjugates consisting of self-assembling cyclic peptides functionalized with 
HPMA (co)polymers were synthesized. Assessment of their assembly properties in solution 
revealed the formation of nanotubes of up to 34 repeating units and ~ 16 nm in length (with an 
estimated aspect ratio of 2.9). Interestingly, the presence of a small fraction of a comonomer 
prone to non-covalent interactions greatly helped the self-assembly process. The comonomer-
containing conjugate that most effectively self-assembled was tested against a non-assembling 
control and clear differences in cell uptake behaviour in vitro and pharmacokinetics in vivo 
were observed. Cellular accumulation studies demonstrated a time and temperature dependent 
internalization of the compounds, with the larger size of the nanotubes increasing uptake into 
tumour cells by a factor 3 to 4 compared to the control polymer. Confocal imaging studies 
confirmed accumulation of the conjugates in the lysosomal compartments of the cells, further 
indicating an endosomal uptake pathway. After intravenous injection to rats, conjugates were 
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found to circulate for 10+ hours, and to exhibit significantly lower clearance and higher plasma 
exposure when compared to the control polymer chains. Such characteristics may enhance 
passive accumulation in EPR positive tumors. Most importantly, conjugates were ultimately 
cleared from the systemic circulation, most likely as a result of slow disintegration of the self-
assembled structures into smaller entities or even unimers. This feature of the conjugates 
certainly helps to avoid undesired long-term accumulation and storage diseases in organs such 
as the liver and spleen. Although drug induced alterations on nanotube properties need to be 
investigated, the present data suggest that cyclic peptide-polymer nanotubes may become a 
valuable type of nanosized drug delivery system.  
Materials and methods 
Materials 
4-Aminomethyl pyridine (98%), 1-amino-2-propanol (95%), methacryloyl chloride (97%), 2-
isocyanatoethyl methacrylate and deuterated solvents for NMR were purchased from Sigma-
Aldrich. Potassium carbonate and anhydrous magnesium sulphate (MgSO4) were purchased 
from Fisher Scientific. 2,2'-Azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride (VA-044) 
was purchased from Wako Chemicals. N-methylmorpholine (NMM, 99 %) was purchased 
from Alfa Aesar. O-(Benzotriazole-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate 
(HBTU) was purchased from Iris Biotech. Methacryloxyethyl thiocarbamoyl rhodamine B 
(Rhodamine methacrylate, RhMA) was purchased from Polysciences. Ethanolamine [1-14C] 
(55 mCi/mmol, 0.1 mCi/mL) was obtained from ARC (American Radio Chemicals). All 
solvents were bought from commercial sources and used as received. Cyclic peptide and chain 
transfer agents CPAETC and E(CPAETC)2 were synthesized according to previously reported 
protocols.46, 68  
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Characterization methods 
NMR spectra were recorded on a Bruker DPX-300 instrument. Molecular weights and 
dispersities of polymers were assessed by size exclusion chromatography (SEC) on a Polymer 
Laboratories PL-GPC 50 Plus system in DMF with 0.1% LiBr, using a poly(methyl 
methacrylate) calibration, using refractive index detection.  
SANS was carried out either on the Sans2d small angle diffractometer at the ISIS Pulsed 
Neutron Source (STFC Rutherford Appleton Laboratory, Didcot, UK)69-70 or on SANS 
Instrument D11 at Institut Laue-Langevin in Grenoble, France. 
On the Sans2d instrument, a collimation length of 4 m and incident wavelength range of 1.75 
– 16.5 Å was employed. Data were measured simultaneously on two 1 m2 detectors to give a 
q-range of 0.0045 – 1.00 Å-1. The small-angle detector was positioned 4 m from the sample 
and offset vertically 60 mm and sideways 100 mm. The wide-angle detector was positioned 
2.4 m from the sample, offset sideways by 980 mm and rotated to face the sample. The wave 
vector, q, is defined as: 
𝑞 =  
4𝜋sin 
𝜃
2
𝜆
       
where θ is the scattered angle and λ is the incident neutron wavelength. The beam diameter was 
8 mm. Samples were prepared at a concentration of 5 mg/mL in deuterated phosphate buffer 
saline (PBS), and were contained in 2 mm path length quartz cells. Each raw scattering dataset 
was corrected for the detectors efficiencies, sample transmission and background scattering 
and converted to scattering cross-section data (𝜕Σ/𝜕Ω vs. q) using the instrument software.71 
These data were placed on an absolute scale (cm-1) using the scattering from a standard sample 
(a solid blend of hydrogenous and perdeuterated polystyrene) in accordance with established 
procedures.72  
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On the D11 instrument, scattering intensities were recorded by a two-dimensional position-
sensitive 3He detector. Three different instrument settings were used corresponding to a wave 
vector 𝑞 = 4𝜋 sin
𝜃
2
𝜆⁄  range of 0.01 < q < 0.5. H2O was used for instrumental calibration. The 
data were placed on an absolute scale (cm-1) using the scattering from a standard sample in 
accordance with established procedures.73 The obtained reduced data was analysed with the 
open access software SASfit.74  
Light scattering measurements were obtained using an ALV-CGS3 system operating with a 
vertically polarized laser with a wavelength of 632 nm. The measurements were taken at 20°C 
over a range of angles (20-150 º). The incremental refractive index, dn/dC, was determined by 
measuring the refractive index of the polymer in water at various concentrations ranging from 
0.25 to 2 mg/mL, using a Shodex RI detector operating at a wavelength of 632 nm.  
Synthetic procedures 
Synthesis of 2-hydroxypropyl methacrylamide (HPMA) 
 
Adapted from Ulbrich et al.75 Potassium carbonate (29 g, 1.1 eq., 0.21 mol) was dispersed in 
120 mL of dry DCM. The mixture was cooled to -10°C with an ice-ethanol bath and 1-amino-
2-propanol (14.5 mL, 1 eq., 0.19 mol) was added. Methacryloyl chloride (18.5 mL, 1 eq., 0.91 
mol) was diluted with 20 mL of dry DCM, and added dropwise to the previous mixture, while 
maintaining the temperature at -10°C. Once the addition was complete, the reaction was left to 
warm up to room temperature and stirred overnight. After filtration and drying over MgSO4, 
the DCM was evaporated and a white solid was obtained. The product was dissolved in 
methanol and washed with hexane, and the methanol phase was evaporated. The obtained solid 
was recrystallized from acetone. Yield: 45% (10.2 g).  1H-NMR (d6-DMSO, 300 MHz, ppm): 
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δ = 7.82 (broad s, 1H, NH) , 5.65 (s, 1H, CH vinyl), 5.31 (s, 1H, CH vinyl), 4.71 (s, 1H, OH), 
3.69 (m, 1H, CH), 3.05 (m, 2H, CH2), 1.85 (s, 3H, CH2=C(CH3)), 1.00 (d, J = 6 Hz, 3H, CH-
CH3). 
13C-DEPT-NMR (d6-DMSO, 75 MHz, ppm): δ = 167.7, 139.9, 118.9, 85.1, 46.7, 21.1, 
18.6. 
 
Synthesis of 2-(3-(pyridin-4-ylmethyl)ureido)ethyl)methacrylate (PUEMA) 
 
2-Isocyanatoethyl methacrylate (2.2 g, 14.15 mmol) and 4-aminomethyl pyridine (1.53 g, 1 
eq., 14.15 mmol) were mixed in dry DCM (10 mL) and left to stir at room temperature for 10 
min. The solvent was evaporated under reduced pressure and PUEMA was collected as a white 
powder. Yield: 95% (3.53 g). 1H-NMR (CDCl3, 300 MHz, ppm): δ = 8.52 (d, 2H, CH-N-CH 
pyridine), 7.19 (d, 2H, CH-C-CH pyridine), 6.09 (s, 1H, CH vinyl), 5.59 (s, 1H, CH vinyl), 
5.13 (broad t, 1H, NH urea), 4.97 (broad t, 1H, NH urea), 4.38 (d, 2H, NH-CH2-pyridine), 4.25 
(t, 2H, O-CH2), 3.53 (q, 2H, O-CH2-CH2), 1.93 (s, 3H, CH3). 
13C-DEPT-NMR (CDCl3, 75 
MHz, ppm): 166.9, 157.5, 149.2, 148.3, 135.3, 125.5, 121.4, 63.4, 42.4, 39.0, 17.6. FTIR: (ν, 
cm-1): 3313 (N-H stretch, urea), 1720 (C=O stretch, methacrylate), 1623 (C=C stretch, alkene), 
1585 (C=O stretch, urea). MS (ESI): [M+Na]+ calculated: 286.1, found: 285.9. 
RAFT polymer synthesis  
Chain transfer agent (CTA, here CPAETC or E(CPAETC)2), monomers (HPMA, PUEMA, 
RhMA), initiator (VA 044) and solvent (70/30 DMSO/H2O) were introduced into a flask 
equipped with a magnetic stirrer and sealed with a rubber septum (see Table S1 for detailed 
conditions). The solution was degassed by bubbling nitrogen through it for 15 min, and then 
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put in an oil bath at 44°C for the indicated time. Conversions were determined by 1H NMR. 
For polymers P5 and P6, conversion of RhMA could not be determined because the extremely 
low amounts did not allow visualization of the corresponding signals. The polymers were 
precipitated in ice-cold acetone and dried under vacuum. The rhodamine-labelled polymers P5 
and P6 were further dialysed to remove any excess dye.   
Conjugation of polymers to the cyclic peptide 
General protocol: cyclic peptide, polymer (2.5 eq.) and HBTU (3.75 eq.) were solubilized in 
DMSO (1.5 mL). NMM (6 eq.) was added and the reaction mixture was left to stir at room 
temperature for 2 hours. After the reaction, DMSO was removed using a stream of N2 and the 
conjugates were dissolved in water and purified from the excess polymer using a centrifugal 
ultrafiltration unit with a molecular weight cut off of 30 kDa (Amicon® Ultra centrifugal filter). 
The isolated conjugates were freeze-dried.    
Radiolabelling of compounds 
Conjugate C3 (or polymer P4) was introduced in a vial, together with CDI (10 eq.) and 
anhydrous DMF (1 mL) and the mixture was stirred for 4 hours. An aliquot of [14C]-labelled 
ethanolamine in ethanol was withdrawn from the bottle (1 eq.) and the ethanol evaporated using 
a steam of nitrogen. DMF was used to redissolve the radiolabel and add it to the mixture, which 
was then stirred for 4 days. The solvent was removed using a stream of nitrogen and the dried-
up mixture was solubilized in water and passed over a size exclusion column (PD10, GE 
Healthcare Life Sciences) to remove most of the remaining free radiolabel prior to dialysis. 
The purity of the radiolabelled compounds C3* and P4* was assessed by HPLC and size 
exclusion chromatography using PD10 cartridges (Figures S8-9). Briefly, 0.7 mL fractions 
were collected and the activity of each fraction was determined by scintillation counting. 
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In vitro testing 
Cells 
A2780 (human ovarian carcinoma), PC3 (human prostate carcinoma) and MDA-MB-231 
(human breast cancer) cells were obtained either from the European Collection of Cell Cultures 
(ECACC) or Sigma-Aldrich. A2780 were grown in Roswell Park Memorial Institute medium 
(RPMI-1640), and PC3 and MDA-MB-231 in Dulbecco’s Modified Eagle Medium (DMEM). 
Both media were supplemented with 10% v/v of foetal calf serum, 1% v/v of 2 mM glutamine 
and 1% v/v penicillin/streptomycin. Cells were grown as adherent monolayers at 37 °C in a 
5% CO2 humidified atmosphere and passaged at approximately 70-80% confluence. 
Growth inhibition assay  
Briefly, 5000 cells were seeded per well in 96-well plates and allowed to grow for 24 h before 
adding different concentrations of the compounds to be tested. Compounds were dissolved 
directly in cell culture medium at concentrations ranging from 0.1 to 500 μg/mL. Culture 
medium was replaced by dilutions of the compounds and cells further incubated for 72 h. After 
this, supernatant was removed and replaced by fresh medium. XTT assay was used to 
determine cell viability. Absorbance measurements of the plate at 475 nm were carried out 
using a Synergy HTX (Biotek) plate reader. Determination of viable treated cells was done in 
comparison to untreated controls. Two independent sets of experiments in triplicates were 
carried out and standard deviations were used for error bars. 
Microscopy  
Cells were seeded in an 8-chamber imaging plate (Eppendorf) at 15000 cells per well and 
incubated overnight at 37 °C with 5% CO2. Rhodamine-labelled conjugate dissolved in PBS 
was added to the wells to a final concentration of 20 μM and incubated for 24 h. Colocalization 
studies were carried out after lysosome staining using Lysotracker® Green DND-26. Labelling 
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was achieved by incubating cells in the presence of Lysotracker (100 nM) for 2 hours. The 
cells were washed 2 times with fresh media and images were recorded using a Leica SP5 Laser-
scanning confocal microscope with a HCX PL APO 40x (NA 1.25) oil objective. Images were 
acquired at 1024x1024, capturing rhodamine (ex 561; em: 565-580 nm), lysotracker GFP (ex 
488; em 504-520 nm) and transmission channels. Image acquisition settings were consistent for 
samples and controls. 
Flow cytometry 
Cells were seeded in 24-well plates at 100 000 cells per well and incubated in 500 μL of 
compound-free media overnight at 37 °C with 5% CO2. Rhodamine-labelled compounds were 
then added to cells in triplicate, achieving a final concentration of 20 μM. Three sets of 
conditions were tested: incubation at 37 °C for 24 h, incubation at 37 °C for 3 h, and incubation 
at 4 °C for 3 h. For the incubation at 4 °C, the cells were placed on ice for 10 min prior to 
addition of the compound, and subsequently in the fridge. After incubation, the culture medium 
was removed, and the cells were washed with PBS, harvested with trypsin, transferred to 
Eppendorf tubes and spun at 1500 g for 5 min. The supernatant was discarded and cell pellets 
were resuspended in PBS, transferred into flow cytometry tubes and stocked on ice until 
measurement. Samples were analysed on a BD FACScan flow cytometer using the FL2 channel 
(585/42 nm). Cells were analysed using forward and side scatter gates to exclude debris and 
cell aggregates. Fluorescence intensity corresponding to untreated cells was subtracted, the 
data were processed using Flowing software 2® and reported values correspond to the average 
of the means of fluorescence for a population of 10000 cells.  
Activity Determination and Scintillation Counting  
The specific activity of the compounds was determined by dilution of known amounts of 
material into PBS. Aliquots were mixed with 4 mL of Ultima Gold and scintillation counted 
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on a Packard Tri-Carb 2000CA liquid scintillation analyzer (Meriden, CT). Polymer P4* and 
conjugate C3* were found to have specific activities of 0.28 µCi/mg and 0.33 µCi/mg, 
respectively.  
Pharmacokinetics and Biodistribution studies  
Animals 
All animal experimental protocols were approved by the Monash Institute of Pharmaceutical 
Sciences Animal Ethics Committee, Monash University, Parkville, VIC, Australia. Male 
Sprague Dawley rats (250-350 g) were used in these experiments. Animals were maintained 
on a 12h light/dark cycle at all times. 
Intravenous Pharmacokinetic Studies 
A day prior to compound administration, each rat was anaesthetised under isoflurane (2-5% 
v/v) and cannulas (polyethylene tubing 0.96 x 0.58 mm, Paton Scientific, Victor Harbour, 
Australia) surgically inserted into the right jugular vein and carotid artery (to facilitate IV 
administration and blood collection respectively) as previously described.76 The rats were 
transferred to individual metabolic cages (to permit separate collection of urine and faeces) and 
allowed to recover overnight prior to dosing. Each animal was fasted up to 14h prior to and up 
to 8h after administration of the IV dose with water provided ad libitum. Prior to injection, 
blank blood samples (0.2 mL) were obtained from the carotid artery. The compounds were 
dissolved in phosphate buffered saline (PBS) and 0.5 mL was administered at a dose of 12 
mg/kg as a slow bolus intravenous injection (1 mL/min) via the jugular cannula. The cannula 
was then flushed with 0.5 mL of heparinized saline to ensure complete infusion of the dose. 
Subsequent blood samples (0.2 mL) were taken at 1, 5, 10, 20, 30, 60, 120, 180, 240, 360, 480, 
and 1440 min after dose administration. Blood samples were placed immediately into tubes 
containing 10 IU of heparin and centrifuged for 5 min at 3500g. Plasma (0.1 mL) was collected, 
29 
 
transferred to a separate vial and mixed with 4 mL of Ultima Gold scintillation cocktail prior 
to scintillation counting.  
Biodistribution Studies 
At the end of the pharmacokinetic studies (24h), animals were humanely killed by injection of 
a lethal dose of sodium pentobarbital (via the jugular vein cannula) and the following tissues 
removed: liver, spleen, pancreas, kidneys, heart, lungs and brain. The tissues were frozen (-20 
C) and stored in pre-weighed polypropylene tubes until processing and analysis. The samples 
were homogenized using a gentleMACS Dissociator (Miltenyi Biotech) with 5 mL of MilliQ 
water. Triplicate samples from each tissue homogenate (typically 50-100 mg of tissue) were 
mixed with 2 mL of Solvable (Perkin Elmer) and the samples placed at 60 °C overnight to 
facilitate tissue digestion. The samples were cooled to room temperature and 200 μL hydrogen 
peroxide (30% w/v) were added to each vial. Samples were left open at room temperature until 
bubbling had ceased. Ultima Gold (10 mL) was then added and the mixture vortexed before 
the samples were stored at 4 °C in the dark, without agitation, for at least 3 days prior to 
scintillation counting. Blank organs also were treated as above to provide for background 
correction. In order to correct for any reduction in radioactivity counting efficacy due to the 
processing of the tissues, an identical second set of samples was processed in the same way but 
the tissue homogenate aliquots were spiked with a known quantity of radiolabel prior to 
addition of Solvable. All samples were then scintillation counted at 12 C.  
A processing efficiency was calculated, using the following equation: 
𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑠𝑝𝑖𝑘𝑒𝑑 𝑡𝑖𝑠𝑠𝑢𝑒𝑑𝑝𝑚 − 𝑡𝑖𝑠𝑠𝑢𝑒𝑑𝑝𝑚,𝑢𝑛𝑐𝑜𝑟𝑟
𝑠𝑝𝑖𝑘𝑒𝑑 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛𝑑𝑝𝑚
 
Where spiked tissuedpm was the mass-corrected radioactivity measured in the spiked samples, 
tissuedpm,uncorr was the mass-corrected radioactivity in the non-spiked tissue samples, and spiked 
solndpm was the known amount of radioactivity added to the spiked sample. Effectively, the 
calculation provides an indication of the efficiency of counting, using the known (spiked) 
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amount of radioactivity in each tissue as a reference. This value for efficiency was used to 
correct the [14C] content in the processed sample using the following equation: 
𝑡𝑖𝑠𝑠𝑢𝑒𝑑𝑝𝑚,𝑐𝑜𝑟𝑟 =
𝑡𝑖𝑠𝑠𝑢𝑒𝑑𝑝𝑚,𝑢𝑛𝑐𝑜𝑟𝑟
𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦
 
The activity in the whole organ was then calculated knowing the mass fraction of the entire 
organ present in the processed sample. The results are expressed as either the percentage of 
injected dose in the organ at sacrifice or the percentage of injected dose per gram of tissue.  
Urine  
Urine, pooled from immediately after dose administration till 24h, was collected at the end of 
the study. A blank urine sample was also collected to provide for background correction. After 
accounting for the volume of pooled urine collected a 100 μL aliquot was taken and mixed with 
4 mL of Ultima Gold and scintillation counted. After background subtraction, the radiolabel 
content of the sample was corrected for the total volume of urine collected and converted to a 
percentage of the total administered dose.  
Calculation of Pharmacokinetic Parameters 
The concentrations of radiolabel in plasma/whole blood samples were converted to microgram 
equivalent concentrations using the specific activity of the radiolabeled compounds. Non-
compartmental pharmacokinetic parameters were calculated with Excel using the PK solver 
add-in.77  The NCA IV Bolus model was used, in which the AUC0-∞ was calculated using the 
linear trapezoidal method. The elimination half-life (t1/2), volume of distribution (Vd) and 
clearance (Cl) were also determined from the model. An estimate of initial distribution volume, 
or volume of central compartment (Vc) was calculated from the dose/Cp
0, where Cp0 was the 
extrapolated concentration in plasma at the moment of completion of the injection. In addition 
to the non compartmental analysis the data was also fitted to a two-compartmental model and 
analysed using Phoenix WinNonlin software (Version 6.3, Cetara). Plasma profiles fitted to 
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the two-compartment model and derived PK parameters are provided in Supporting 
Information.  
Associated content 
Supporting Information available: details on synthesis (schemes and polymerization 
conditions), SANS and SLS analyses, additional characterization (SEC, HPLC, determination 
of fluorescence correction factors), complementary pharmacokinetics analysis.  
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